BE2017C021I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C021I2
BE2017C021I2 BE2017C021C BE2017C021C BE2017C021I2 BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2 BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 C BE2017C021 C BE 2017C021C BE 2017C021 I2 BE2017C021 I2 BE 2017C021I2
Authority
BE
Belgium
Application number
BE2017C021C
Other languages
Dutch (nl)
Original Assignee
Sk Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Bioscience Co Ltd filed Critical Sk Bioscience Co Ltd
Publication of BE2017C021I2 publication Critical patent/BE2017C021I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2017C021C 2003-01-28 2017-06-19 BE2017C021I2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide

Publications (1)

Publication Number Publication Date
BE2017C021I2 true BE2017C021I2 (ja) 2023-03-07

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C021C BE2017C021I2 (ja) 2003-01-28 2017-06-19

Country Status (14)

Country Link
US (1) US7041635B2 (ja)
EP (2) EP2253645B1 (ja)
KR (1) KR100642293B1 (ja)
CN (1) CN100404552C (ja)
AU (1) AU2003274766B8 (ja)
BE (1) BE2017C021I2 (ja)
CA (1) CA2514646C (ja)
DK (2) DK2253645T3 (ja)
ES (1) ES2446041T3 (ja)
FR (1) FR17C1024I2 (ja)
HK (1) HK1150840A1 (ja)
LU (1) LUC00023I2 (ja)
NL (1) NL300878I2 (ja)
WO (1) WO2004067566A1 (ja)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101379077A (zh) 2005-12-07 2009-03-04 夏洛特·豪泽 因子ⅷ和因子ⅷ-类似蛋白的小肽或者拟肽亲合性配体
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
AU2007269233B2 (en) * 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR101389376B1 (ko) 2007-02-23 2014-04-29 에스케이케미칼주식회사 제 ８ 인자 및 그의 유도체의 제조 및 정제 방법
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
RU2531493C2 (ru) 2007-11-01 2014-10-20 Юниверсити Оф Рочестер Рекомбинантный фактор viii, обладающий повышенной стабильностью
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
CN104059155A (zh) * 2008-05-16 2014-09-24 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2776503C (en) 2009-10-02 2020-07-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
EP4382170A2 (en) 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
KR101948337B1 (ko) * 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
AR087091A1 (es) 2011-07-08 2014-02-12 Biogen Idec Hemophilia Inc Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9394353B2 (en) 2011-10-18 2016-07-19 Csl Limited Method for improving the stability of purified factor VIII after reconstitution
WO2013057171A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
JP6072810B2 (ja) 2011-10-18 2017-02-01 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
LT2882450T (lt) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
RS61387B1 (sr) 2013-02-15 2021-02-26 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3013358A4 (en) 2013-06-28 2017-03-22 Biogen MA Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
CN116731201A (zh) 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
WO2015107222A1 (en) * 2014-01-20 2015-07-23 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
KR102192494B1 (ko) 2014-08-04 2020-12-18 시에스엘 리미티드 인자 viii 제형
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
AU2016266627A1 (en) 2015-05-22 2018-01-18 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
KR20180012303A (ko) 2015-05-22 2018-02-05 체에스엘 베링 리컴비넌트 퍼실리티 아게 변형된 폰 빌레브란트 인자의 제조 방법
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
MY190067A (en) 2015-11-13 2022-03-24 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
JP6695426B2 (ja) 2015-11-13 2020-05-20 バクスアルタ インコーポレイテッド 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
EP3476860A4 (en) 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018087267A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
MA46968A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
UY38160A (es) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc Partículas implantables y métodos relacionados
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US20220333135A1 (en) 2018-07-16 2022-10-20 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP2022501373A (ja) * 2018-09-19 2022-01-06 セル マシン，インコーポレイテッド 改善された第ｖｉｉｉ因子長期半減期凝固複合体に関連する方法および組成物
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
MA54951A (fr) 2019-02-15 2021-12-22 Bayer Healthcare Llc Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
EP3938742A1 (en) 2019-03-14 2022-01-19 Terumo BCT Biotechnologies, LLC Multi-part lyophilization container and method of use
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
MX2021015897A (es) 2019-06-19 2022-04-18 Bioverativ Therapeutics Inc Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2021156833A (ja) 2020-03-30 2021-10-07 シスメックス株式会社 血液凝固活性の測定方法
EP4355768A1 (en) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a

Also Published As

Publication number Publication date
EP2253645A3 (en) 2011-02-16
ES2446041T3 (es) 2014-03-06
CN1745100A (zh) 2006-03-08
CA2514646A1 (en) 2004-08-12
DK2253645T3 (en) 2016-06-27
EP1587832B1 (en) 2013-12-11
FR17C1024I2 (fr) 2019-07-19
HK1150840A1 (zh) 2012-01-13
EP2253645B1 (en) 2016-03-23
DK1587832T3 (en) 2014-02-24
EP1587832A1 (en) 2005-10-26
KR100642293B1 (ko) 2006-11-03
WO2004067566A1 (en) 2004-08-12
NL300878I2 (nl) 2017-11-02
CA2514646C (en) 2013-07-23
EP2253645A2 (en) 2010-11-24
US7041635B2 (en) 2006-05-09
LUC00023I2 (ja) 2017-09-08
LUC00023I1 (ja) 2017-06-21
US20040147436A1 (en) 2004-07-29
CN100404552C (zh) 2008-07-23
FR17C1024I1 (ja) 2017-09-08
AU2003274766A1 (en) 2004-08-23
AU2003274766B2 (en) 2009-02-12
AU2003274766B8 (en) 2009-08-27
KR20050044776A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
FR17C1024I1 (ja)
BE2015C007I2 (ja)
BE2014C055I2 (ja)
BE2014C027I2 (ja)
BE2014C003I2 (ja)
BE2013C075I2 (ja)
BE2013C069I2 (ja)
BE2013C067I2 (ja)
BE2013C038I2 (ja)
BE2013C036I2 (ja)
BE2011C030I2 (ja)
IN2005DE03350A (ja)
BE2015C005I2 (ja)
BE2012C053I2 (ja)
JP2003288983A5 (ja)
JP2003249721A5 (ja)
DE602004016566D1 (ja)
JP2003274334A5 (ja)
JP2003297751A5 (ja)
JP2004226678A5 (ja)
JP2004228510A5 (ja)
AU2003207750A1 (ja)
AU2002348177A1 (ja)
AU2002355123A1 (ja)
AU2003210772A1 (ja)